MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Stability Notes

Store in tightly closed containers.

Provenance

This compatibility recommendation is derived from Crestor 20mg tablets (AstraZeneca UK Ltd).

Stability Notes

Store in tightly closed containers.

Provenance

This compatibility recommendation is derived from Crestor 40mg tablets (AstraZeneca UK Ltd).

Stability Notes

Does not require any special storage conditions.

Provenance

This compatibility recommendation is derived from Prezista 800mg tablets (Janssen-Cilag Ltd).

Stability Notes

Protect from light. Store in an airtight container.

Provenance

This compatibility recommendation is derived from Proscar 5mg tablets (Organon Pharma (UK) Ltd).

Stability Notes

Protect from moisture. Store in an airtight container.

Provenance

This compatibility recommendation is derived from Yentreve 20mg gastro-resistant capsules (Eli Lilly and Company Ltd).

Stability Notes

Store in an airtight container and protect from light.

Provenance

This compatibility recommendation is derived from Baraclude 0.5mg tablets (Bristol-Myers Squibb Pharmaceuticals Ltd).

Stability Notes

Store in an airtight container and protect from light.

Provenance

This compatibility recommendation is derived from Baraclude 1mg tablets (Bristol-Myers Squibb Pharmaceuticals Ltd).

Stability Notes

Store in an airtight container and protect from light.

Provenance

This compatibility recommendation is derived from Circadin 2mg modified-release tablets (Flynn Pharma Ltd).

Stability Notes

Use airtight and light resistant container.

Provenance

Compatibility information derived from Naprosyn EC 250mg tablets (Atnahs Pharma UK Ltd).

Print this list

Medicines under this category are suitable for use inside MCAs, although this is likely to be an off-label use.
Medicines under this category can theoretically be used inside an MCA; however, mitigations may need to be considered.
Medicines under this category are not suitable for use inside MCAs.
We do not have stability information for these medicines and therefore cannot make a recommendation on suitability in an MCA.